CARA Stock Recent News

Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended to 2027 by the US Medicare and Medicaid Services, potentially boosting the company's stock value. Despite a net loss of $26.7 million in Q1 2023, Cara Therapeutics has launched Kapruvia in several European countries and is progressing with Phase 3 trials for other potential treatments, indicating an active R&D pipeline. The company's financial outlook remains risky with ongoing losses and uncertainties in drug development, leading to a 70% stock devaluation since February. Cara remains a "Sell".

Small-cap stocks, defined by a market capitalization between $300 million and $2 billion, can tempt investors looking for quick returns. However, these small-cap stocks to avoid can be incredibly volatile as they are lucrative, making them a potential danger zone for the unwary investor.

STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.

While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Christopher Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler Chi Fong - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon. My name is Lateef, and I will be your conference facilitator.

Cara Therapeutics (CARA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.52 per share a year ago.

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,

STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler AJ Velasquez-Mao - Jefferies Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Oren Livnat - H.C.